WHO Prequalification for Shanchol® Vaccine Secures Global Supply
WHO Prequalification for Shanchol® Vaccine Secures Global Supply
Hyderabad, India - Shanchol®, an oral cholera vaccine developed by Shantha Biotechnics, has attained prequalification from the World Health Organization (WHO). This achievement facilitates procurement by various global health organizations such as UNICEF, Gavi, and PAHO, allowing them to distribute Shanchol® in regions where cholera poses a significant threat to public health.
Significance of WHO Prequalification
The prequalification from WHO is pivotal for Shanchol® as it assures communities of a reliable supply of this essential vaccine. By enabling international agencies to purchase certified vaccines, the WHO prequalification aims to bolster vaccination efforts and contain cholera outbreaks globally. Dr. K.I. Varaprasad Reddy, founder of Shantha Biotechnics, expressed that this development aligns with the original vision of creating affordable solutions for countries facing frequent cholera challenges.
History and Impact of Shanchol®
Over the years, close to 40 million doses of Shanchol® have made their way through various vaccination campaigns led by UNICEF. Following a pause in production due to changes in ownership and management, GCBC Vaccines Pvt. Ltd. resumed the manufacturing of Shanchol®. The WHO's on-site inspection reaffirmed the company's commitment to maintaining safety and quality in vaccine production, culminating in the crucial prequalification of this life-saving vaccine.
Leadership Insights on Vaccine Availability
Dr. Ravi Penmetsa, Managing Director of GCBC Vaccines Pvt. Ltd., spoke about the significance of continuing production. He emphasized that India's sterile manufacturing capabilities can substantially contribute to global healthcare. Through the recommencement of Shanchol® production, the goal is to adhere to high standards of quality and reliability, ensuring that communities worldwide have access to this vaccine.
Commitment to Global Health
Dr. Vishy Chebrol, Executive Director of GCBC Vaccines Pvt. Ltd., highlighted the organization's unwavering commitment to global health. The focus is on guaranteeing that vaccines like Shanchol® are made accessible to the countries that need them most, in a reliable and cost-effective manner. Beyond Shanchol®, GCBC Vaccines is actively working to bring other innovative vaccines from their pipeline into international markets, thus continuing the legacy of improving global health.
Understanding Shanchol®
Shanchol® operates as a bivalent killed whole-cell oral cholera vaccine and effectively targets Vibrio cholerae O1 and O139. Its role has been critical in UNICEF-coordinated outbreak responses and preventive immunization efforts, safeguarding millions worldwide against cholera. With the newly secured WHO PQ, Shanchol® aims to meet increasing global demands and fulfill country-specific immunization requirements.
The Legacy of Shantha Biotechnics
Initially founded in the 1990s, Shantha Biotechnics became one of India's foremost biotechnology firms. The company was recognized globally after its acquisition by Sanofi in 2009, marking a significant leap in its stature as a vaccine supplier. The recent acquisition of Shantha's facilities, including those for Shanchol®, by GCBC Vaccines Pvt. Ltd. represents a revival and dedication to furthering Shantha's mission of providing high-quality and affordable vaccines. This new chapter aims to expand access to essential immunizations across the globe.
Frequently Asked Questions
What is Shanchol®?
Shanchol® is an oral cholera vaccine developed to combat cholera outbreaks globally, effective against two specific strains of the bacteria.
What does WHO prequalification mean for Shanchol®?
WHO prequalification indicates that Shanchol® meets international quality standards, enabling procurement by various health organizations for broader distribution.
Why is Shanchol® important in cholera outbreaks?
Shanchol® plays a crucial role in vaccination campaigns aimed at controlling cholera outbreaks, protecting millions in vulnerable regions from the disease.
How many doses of Shanchol® have been supplied worldwide?
Approximately 40 million doses of Shanchol® have been distributed globally through various vaccination initiatives led by UNICEF.
Who manufactures Shanchol® now?
Shanchol® is currently manufactured by GCBC Vaccines Pvt. Ltd., which has resumed production and continues to adhere to high standards of quality and safety.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.